Current guideline-based diagnosis and management, from the discriminatory hCG zone to the unknown site pregnancy algorithm, from methotrexate protocols to interstitial and cesarean scar pregnancy.
⚕️ Target audience: This clinical review is intended for physicians and healthcare professionals; It is a summary of current literature and guidelines for educational purposes. Clinical decisions should be made based on patient-specific evaluation and applicable institutional protocols.
Ectopic pregnancy is a pregnancy located outside the uterine cavity. The majority of them are in the fallopian tube; Extratubal locations include cervical, interstitial, ovarian, and abdominal pregnancy. Its clinical significance arises from a single fact: rupture causes life-threatening bleeding, and ruptured ectopic pregnancy is the leading cause of pregnancy-related maternal deaths in the first trimester—most of these deaths occur before arrival at the hospital or near arrival at the emergency room. Therefore, at the heart of ectopic pregnancy management is a single question: where is the pregnancy?
The most common presentation is first trimester vaginal bleeding and/or abdominal pain; Ectopic pregnancy can also be asymptomatic. In a retrospective study examining 2,026 pregnant women who presented to the emergency department with first trimester bleeding and/or abdominal pain, 376 (18%) were diagnosed with ectopic pregnancy; Of these 376 patients, 76% had vaginal bleeding and 66% had abdominal pain. Symptoms typically appear 6–8 weeks after the last normal menstrual period; Pain begins when the tube is sufficiently stretched, usually at 5–7 weeks. In France's population-based ectopic pregnancy registry system, the incidence of rupture was reported as 18% (UpToDate, ectopic pregnancy, 2026).
Neither the bleeding pattern nor the pain pattern is pathognomonic for ectopic pregnancy. Bleeding ranges from spotting to hemorrhage and is most often caused by shedding of decidualized endometrium rather than the tube itself. The pain is usually in the pelvis and may be diffuse or unilateral; If intraperitoneal blood reaches the diaphragm, pain referred to the shoulder may occur, and if it accumulates in the Douglas space, a feeling of defecation may occur (UpToDate, ectopic pregnancy, 2026).
The absence of risk factors does not exclude the diagnosis. Risk factors that should be questioned are previous ectopic pregnancy, tubal pathology or surgery (pelvic inflammatory disease, tubal ligation), current intrauterine device use, and in vitro fertilization—but more than 50% of patients have no identifiable risk factors (UpToDate, ectopic pregnancy, 2026). Ectopic pregnancy should be considered in every patient of reproductive age with bleeding/pain, unless intrauterine pregnancy has been confirmed.
The most valuable examination in determining the location of pregnancy is transvaginal ultrasonography (TVUSG) and should be performed at the time of application. Findings are evaluated at three levels.
| Finding | Diagnostic value |
|---|---|
| Gestational sac containing yolk sac or embryo outside the uterus (with or without a heartbeat) | Diagnostic — most specific finding (UpToDate, ectopic pregnancy, 2026) |
| Complex, inhomogeneous extraovarian adnexal mass | Suggestive, not diagnostic. It is the most common finding; found in 89% or more of cases (UpToDate, ectopic pregnancy, 2026) |
| Extraovarian adnexal mass containing empty gestational sac ("tubal ring") | Suggestive, non-diagnostic |
| Gestational sac alone (no yolk sac or embryo) | Neither diagnostic of intrauterine nor ectopic pregnancy — strongly suggestive of early intrauterine pregnancy |
| Fluid with debris in the Douglas cavity and/or abdomen | May be compatible with rupture; but is non-specific — also seen in healthy individuals and ruptured ovarian cyst |
Diagnosis is confirmed by visualization of the yolk sac or embryo-containing sac outside the uterus, or by the absence of pregnancy product in uterine aspiration in the presence of positive serum hCG and subsequent elevation or plateau of hCG. The reported sensitivity of TVUSG in detecting ectopic pregnancy when serum hCG is >2000 mIU/mL is 10.9% and specificity is 95.2% (UpToDate, ectopic pregnancy, 2026) — meaning that negative ultrasonography does not exclude ectopic pregnancy.
🔴 No patient should be diagnosed or treated for ectopic pregnancy based on a single serum hCG value. The discriminatory zone is the level of hCG at which the gestational sac is expected to be seen if an intrauterine pregnancy is present—a line of probability, not a diagnostic threshold.
UpToDate uses the 3510 mIU/mL discriminatory zone for TVUSG; some institutions put the threshold at 2000 mIU/mL. The difference balances the two types of errors against each other: raising the threshold to 3510 ensures that a viable intrauterine pregnancy is not missed, but increases the risk of delaying the diagnosis of ectopic pregnancy. In a study of 651 patients with first trimester bleeding or pain, the gestational sac in live intrauterine pregnancies was seen in 80% of pregnancies when hCG was 1500 mIU/mL, in 91% when hCG was 2000 mIU/mL, and in 99% when hCG was 3510 mIU/mL—that is, 1% of intrauterine pregnancies still could not be visualized when the threshold was set at 3510 (Connolly 2013, Obstet Gynecol ). The experience of the ultrasonographer, device quality, myoma, multiple pregnancy and body structure also affect the detection. Multiple pregnancy should always be in the differential diagnosis when intrauterine pregnancy is not observed when hCG is above the discriminatory zone; Values above 9000 mIU/mL, which cannot be visualized with TVUSG, have been reported in intrauterine triple pregnancy (UpToDate, ectopic pregnancy, 2026).
Abnormal rise is defined as an increase of less than 35% in two days in UpToDate; The <50% threshold used historically was based on a limited number of patients. In patients with baseline hCG below 10,000 mIU/mL, the expected rate of increase at 48 hours depends on the baseline (Barnhart 2016, Obstet Gynecol):
| Baseline serum hCG | Expected increase in 48 hours |
|---|---|
| <1500 mIU/mL | 49% |
| 1500–3000 mIU/mL | 40% |
| >3000 – <10,000 mIU/mL | 33% |
In normal intrauterine pregnancy, hCG rises curvilinearly until approximately the 41st day, then increases more slowly, peaking around the 10th week, and plateauing in the second and third trimesters (Barnhart 2004, Obstet Gynecol). Serum progesterone is not measured routinely: it is higher in viable intrauterine pregnancies than in ectopic pregnancies, but the definition of "low progesterone" is not clear and measurement in practice does not go beyond confirming the impression given by hCG and TVUSG (UpToDate, ectopic pregnancy, 2026).
A patient with a positive pregnancy test but in whom neither intrauterine nor extrauterine pregnancy can be visualized on TVUSG is classified as pregnancy of unknown location (PUL). This is not a diagnosis, but a waiting situation: the picture may be early intrauterine pregnancy, ectopic pregnancy or early failed intrauterine pregnancy. In the hemodynamically stable patient, follow-up is carried out by serial hCG measurement and repeat ultrasonography. Probability calculators (mathematical models such as M4, M6-P) can be used to estimate risk; In 2185 patients presenting to the emergency department with less than 13 weeks of pregnancy, a Bayesian model-based algorithm correctly classified 98.9% of patients (UpToDate, ectopic pregnancy, 2026).
Diagnostic uterine aspiration confirms intrauterine location of pregnancy (other than heterotopic pregnancy) if trophoblastic tissue is obtained and avoids unnecessary methotrexate use in approximately 30% of patients without an ectopic pregnancy. In contrast, aspiration carries the risk of terminating a live pregnancy and creating intrauterine adhesions; A decision analysis comparing cost and complication found no significant superiority between the two approaches (UpToDate, ectopic pregnancy, 2026).
Rupture should be suspected in the presence of sudden-onset severe and persistent abdominal or pelvic pain, shoulder pain (diaphragmatic irritation), lightheadedness/syncope, hypotension, or tachycardia. In young, healthy patients, vital signs—including orthostatic changes—may remain normal early in significant hemorrhage because of compensatory mechanisms (UpToDate, ectopic pregnancy, 2026). Physical examination is often normal or shows only lower abdominal tenderness; with substantial hemorrhage, abdominal distension and rebound tenderness may be present.
Focused transabdominal ultrasonography rapidly evaluates intraperitoneal bleeding. In the absence of trauma, detection of intraperitoneal bleeding in a woman of reproductive age is considered a ruptured ectopic pregnancy until proven otherwise and requires urgent surgical consultation. If hemoperitoneum is not detected, the cause of the patient's instability is most likely not a ruptured ectopic pregnancy. Laboratory: complete blood count, serum hCG, Rh blood group and crossmatch. If rupture is suspected, the patient is transferred to a center where resuscitation and emergency surgery can be performed; A full pelvic examination is not always possible in the emergency department and may be postponed to the operating room (UpToDate, ectopic pregnancy, 2026).
| Option | Eligible patient | Exclusionary circumstances |
|---|---|---|
| Methotrexate (MTX) | Hemodynamic stability · serum hCG ≤5000 U/L · No fetal cardiac activity on TVUSG · compliance with monitoring and access to emergency healthcare. The criterion of mass <3–4 cm is widely used but has not been validated as a predictor of success (ACOG PB 193, 2018) | Hemodynamic instability · intrauterine pregnancy (including heterotopic with viable intrauterine pregnancy) · sign/sign of rupture · significant haematological, renal or liver laboratory abnormality · immunodeficiency, active lung disease, peptic ulcer · MTX hypersensitivity · breast-feeding |
| Surgery | Urgent: hemodynamic instability, sign/sign of rupture. Elective: MTX contraindication, MTX failure, desire for concurrent surgery (permanent contraception, hydrosalpinx removal), heterotopic pregnancy with viable intrauterine pregnancy | If TVUSG does not clearly show an adnexal mass suggestive of tubal pregnancy or ectopic in a hemodynamically stable patient, surgery is not performed — if the mass is not visualized, it is possible that it will not be found during surgery (UpToDate, ectopic pregnancy, 2026) |
| Standby monitoring | No symptoms or signs of impending rupture · Confirmed or strongly suspected tubal ectopic pregnancy on TVUSG · serum hCG is low and falling (>10% decrease in two consecutive measurements) · compliance with monitoring | The hCG threshold varies across institutions—ACOG recommends it for patients who meet the criteria and have hCG <200 mIU/mL (88% of these patients resolve spontaneously); higher thresholds such as 1000–2000 mIU/mL have also been used in the literature (ACOG PB 193, 2018; van Mello 2013, Hum Reprod; Solangon 2023) |
The effectiveness of methotrexate is comparable to surgery and fertility outcomes are similar. In a systematic review of randomized trials, a single dose of systemic MTX (50 mg/m² or 1 mg/kg) was less successful than laparoscopic salpingostomy (four studies; 71% vs 88%; RR 0.82; 95% CI 0.72–0.94); However, when a single dose was insufficient, the efficacy was equalized when an additional dose was given (RR 1.01; 95% CI 0.92–1.12). There was no significant difference between a fixed multiple-dose regimen and surgery (one study; 82% vs 71%; RR 1.15; 95% CI 0.93–1.43) (Mol 2008, Hum Reprod Update).
The most important determinant of MTX failure is a high hCG level. In a systematic review of 503 patients, failure was significantly higher in those with baseline hCG >5000 U/L than in those with <5000 U/L (OR 5.5; 95% CI 3.0–9.8); The 5000–9999 U/L group failed more often than the 2000–4999 U/L group (OR 3.8; 95% CI 1.2–12.3) — representing one more failure per 10 treatments (Menon 2007, Fertil Steril ). The second strong factor is fetal cardiac activity: it was significantly associated with failure in the meta-analysis (OR 9.1; 95% CI 3.8–22.0) (Barnhart 2003, Obstet Gynecol). Although mass size (≥3.5 cm) is a frequently used exclusion criterion, it is based on small studies with inconsistent protocols and mass size does not appear to correlate with hCG level (UpToDate, ectopic pregnancy, 2026).
Pre-treatment evaluation: physical examination and history, serum hCG, TVUSG, blood group and screening, complete blood count and kidney (creatinine) and liver (ALT, AST) function tests (UpToDate, ectopic pregnancy, 2026). Protocols get their name from the number of doses targeted, not the number of doses actually required.
| Protocol | Dosing schedule | Monitoring and success criteria |
|---|---|---|
| Single dose (preferred by most patients) | Day 1: MTX 50 mg/m² IM (maximum 100 mg with normal renal function) | hCG days 1, 4 and 7. Second dose if drop <15% on days 4 to 7. An increase in hCG from Days 1 to 4 is normal. If there is a ≥15% decrease between days 7 and 14, weekly monitoring until it decreases to an undetectable level; If <15%, additional dose. 15–20% of patients require a second dose, less than 1% receive more than two doses; A maximum of three doses are given. No leucovorin required (Lipscomb 2005, Am J Obstet Gynecol) |
| Two doses | Day 1 and day 4: MTX 50 mg/m² IM | hCG days 1, 4 and 7. If there is a >15% decrease from the previous measurement on day 7, stop treatment and proceed with weekly monitoring; If <15%, third dose on day 7, fourth dose on day 11 if necessary. Defined for selected patients with hCG >3000 U/L or adnexal mass >2 cm (UpToDate, ectopic pregnancy, 2026) |
| Multiple dose (interstitial pregnancy) | MTX 1 mg/kg IM/IV days 1, 3, 5, 7 + leucovorin 0.1 mg/kg IM days 2, 4, 6, 8 (maximum 100 mg) | hCG days 1, 3, 5 and 7. When there is a >15% decrease from the previous measurement, treatment is stopped and monitoring switches to weekly intervals. In a meta-analysis of 124 patients, the average resolution time was 54±32 days, complete resolution was 82% (UpToDate, ectopic pregnancy, 2026) |
It takes time for hCG to decline to undetectable levels: in a retrospective study of 216 patients, the median time after a single dose of MTX was 22 days and depended on baseline (20 days for baseline hCG <1000 IU/L, 34.5 days for >2000 IU/L) (UpToDate, ectopic pregnancy, 2026). Routine serial ultrasonography has no clinical benefit: after treatment, the ectopic mass often enlarges and persists for weeks; this most likely reflects hematoma and does not predict failure. Ultrasonography for peritoneal fluid evaluation is indicated in the patient with severe abdominal pain (UpToDate, ectopic pregnancy, 2026).
Post-MTX patient instructions: avoid vaginal intercourse and new pregnancy until hCG is undetectable · avoid pelvic examination during monitoring (theoretical risk of rupture) · sun protection due to risk of MTX dermatitis · avoid vitamins containing folic acid · avoid NSAIDs (which may reduce renal excretion of MTX and increase toxicity). Pain counseling: Mild to moderate abdominal pain lasting 1–2 days is common 6–7 days after MTX and is usually controlled with paracetamol; It reflects stretching due to tubal abortion or hematoma. On the other hand, severe pain is worrisome in terms of rupture. Three parameters predicted hemoperitoneum ≥300 mL in one study: moderate-to-severe pelvic pain, fluid above the uterine fundus or around the ovary, and hemoglobin <10 g/dL. If none of the three are present, the probability is 5.3%; 92.6% if two or three are present (UpToDate, ectopic pregnancy, 2026). The fact that hCG is falling does not exclude the possibility of rupture. Pain alone is not an indication for surgery in a hemodynamically stable patient.
There are two surgical options for tubal pregnancy: salpingectomy (removal of the tube) and salpingostomy (incising the tube and removing the pregnancy, preserving the rest of the tube). Although salpingectomy is the traditional standard, salpingostomy is associated with a higher rate of subsequent intrauterine pregnancy: in a meta-analysis of 24 randomized trials involving 2354 patients, salpingostomy was superior to salpingectomy for subsequent intrauterine pregnancy (OR 2.49; 95% CI 1.61–3.86; 15 studies) (UpToDate, ectopic pregnancy, 2026), while rates of repeat ectopic pregnancy were similar. Most surgeries are performed minimally invasively; Laparoscopy can often be performed even in the presence of hemoperitoneum and active bleeding.
The risk of persistent ectopic pregnancy is higher in salpingostomy: 3–20% in case series and 2% in a retrospective study of 2498 patients who underwent salpingostomy (UpToDate, ectopic pregnancy, 2026). Risk factors are surgeon inexperience, partial removal of pregnancy tissue, and deep infiltration of trophoblast into the tubal wall. Therefore, after salpingostomy, hCG is monitored weekly until it decreases to an undetectable level; If the postoperative day 7 value has decreased by less than 15% compared to the 4th day, hCG is rising, or there is no decrease for a week, persistent ectopic pregnancy is suspected and MTX is given. If pathology confirms tubal pregnancy after salpingectomy, postoperative hCG monitoring is not required (UpToDate, ectopic pregnancy, 2026).
The interstitial segment is the proximal part of the tube embedded in the uterine muscular wall. The terms "cornual" and "angular" should be avoided—these terms do not describe ectopic pregnancy, but rather intrauterine pregnancies that tend to end in miscarriage rather than rupture. The main sonographic findings are: eccentric location of the gestational sac close to the uterine cornua, myometrial mantle thinner than 5 mm, failure of the myometrium or endometrium to completely surround the sac, and the “interstitial line sign”—an echogenic line extending from the upper-outer point of the endometrial cavity to the middle of the interstitial mass. In small series, this sign has been reported to be more useful than eccentric sac placement and myometrial thinning.
Since the interstitial segment can expand more easily than other tubal segments, pain occurs later in pregnancy, usually at 8–10 weeks; rupture occurs in approximately 20–50% of cases (UpToDate, ectopic pregnancy, 2026). While maternal mortality has decreased in tubal pregnancy, the rate remains at 2.0–2.5% in interstitial pregnancy—primarily because these pregnancies are mistaken for intrauterine pregnancies. Treatment: multiple-dose MTX protocol (above) or surgery; in a retrospective study of 76 patients, systemic MTX success was 31%, whereas local MTX injection achieved 70% (UpToDate, ectopic pregnancy, 2026). Cornuostomy is preferred in surgery, and cornual resection is performed if necessary. The risk of uterine rupture in a subsequent pregnancy must be discussed: uterine rupture in a subsequent pregnancy developed in three cases in a series of 10 patients who underwent cornual resection, and in two cases in another series of 33 patients (UpToDate, ectopic pregnancy, 2026). Close antenatal monitoring is mandatory in these patients, and counseling is provided regarding planned cesarean delivery at term to avoid the risk of rupture during labor.
Heterotopic pregnancy, which is simultaneous intrauterine and extrauterine pregnancy, is rare; It has a remarkable frequency in those who become pregnant with assisted reproductive techniques. Serial hCG measurements are not instructive because they largely reflect the production of intrauterine pregnancy. The diagnosis is suggested by the observation of both intrauterine pregnancy and a complex adnexal mass, non-endometrial gestational sac or echogenic fluid in the Douglas space on ultrasonography; It is confirmed if the adnexal mass or sac contains yolk sac or embryo. Diagnosis is often delayed (until the 16th week) because the possibility of an additional ectopic pregnancy is usually not considered when an intrauterine pregnancy is seen on ultrasonography.
Systemic methotrexate is contraindicated in heterotopic pregnancy accompanied by a viable and desired intrauterine pregnancy. The standard surgical approach for tubal localization is salpingectomy and is the first option if there is evidence of hemodynamic instability or rupture. In the unruptured case, ultrasound-guided local feticidal injection (potassium chloride—e.g., 2 mL of a 2 mEq/mL solution—or hyperosmolar glucose) is an option in experienced hands; However, in a review of 11 heterotopic cases treated with potassium chloride, treatment failed in 6 (55%) and required surgery (UpToDate, ectopic pregnancy, 2026). The cardiac activity of the intrauterine fetus is confirmed by ultrasonography 1–2 weeks after both approaches. The risk of miscarriage in an intrauterine pregnancy in a heterotopic pregnancy appears to be higher than in an isolated intrauterine pregnancy.
Caesarean section (or myomectomy) scar pregnancy is the complete or partial implantation of the gestational sac into the previous hysterotomy scar. It is a separate entity from ectopic pregnancy—it takes place within the uterine cavity—but its morbidity is high and its frequency is increasing with the increase in cesarean section rates. In a systematic review of expectant cases (47 studies, 194 patients with known pregnancy outcome), the results were as follows: miscarriage 20.1% · fetal death 8.3% · term birth 25.8% · preterm birth 41.8% (13.9% before 34 weeks) · hysterectomy 52.6%. The placenta accreta spectrum is common in these pregnancies and further increases the rates of fetal death, preterm birth, hysterectomy, hemorrhagic morbidity, and surgical complications. In the review, it was reported that sonographic signs such as type II–III classification, "crossover sign − 1", "in-niche" location and low myometrial thickness may be associated with worse outcome, but it was emphasized that these signs should be confirmed (Silva 2023, Eur J Obstet Gynecol Reprod Biol).
Routine antenatal care does not include serial hCG measurement or early TVUSG. The exception is patients at high risk for ectopic pregnancy: in vitro fertilization pregnancy, pregnancy after tubal reconstructive surgery and a history of previous ectopic pregnancy. These patients are monitored with serial serum hCG and TVUSG starting from the first missed menstrual period or embryo transfer; The aim is to diagnose before rupture.
Ectopic localization is usually due to anatomical and functional changes in the tubes caused by clinical or subclinical salpingitis; These changes are typically bilateral and permanent. Therefore, ectopic pregnancy may be followed by subfertility and recurrence. Age over 35, history of infertility and tubal damage negatively affect subsequent reproductive success.
| Outcome | Data |
|---|---|
| Two-year cumulative intrauterine pregnancy (1064 patients) | Salpingectomy 67% salpingostomy 76% medical treatment 76% (UpToDate, ectopic pregnancy, 2026) |
| Live births (17,090 tubal ectopic pregnancies) | Medical 51.6% vs surgical 45.1% (OR 1.30; range is not written because two different 95% CIs are given for this outcome in the source) |
| Two-year cumulative repeat ectopic pregnancy (1064 patients) | Salpingostomy or salpingectomy 18.5% · medical treatment 25.5% |
| Repeat ectopic pregnancy (17,090 cases) | Medical 7.4% vs surgical 6.4% (OR 1.17; 95% CI 1.04–1.32) |
| Risk of recurrence after two ectopic pregnancies | 10%–27 |
| Cumulative outcome at 12 months (328 patients) | Pregnancy 66% intrauterine pregnancy 56% ectopic pregnancy 13% live birth 31% (UpToDate, ectopic pregnancy, 2026) |
Cohort data suggest an increased risk of preterm birth, low birth weight, abruptio placenta, and placenta previa following a first pregnancy resulting in an ectopic pregnancy (UpToDate, ectopic pregnancy, 2026); The risk of detachment was particularly evident in older patients (RR 1.42; 95% CI 1.16–1.69).
When is pregnancy due again? After surgical treatment, the UpToDate application allows a trial from the next menstrual period; If pregnancy does not occur within 12 months, in vitro fertilization is directed. The safe interval after methotrexate is unclear: UpToDate recommends waiting three months, toxicology literature suggests a washout period of 4–6 months—but in a retrospective study of 125 patients who conceived after MTX, rates of fetal malformation and adverse outcomes were similar in those who conceived before and after 6 months. Methotrexate does not appear to affect ovarian reserve and subsequent fertility rates: in a meta-analysis covering seven observational studies and 327 patients, the number of oocytes retrieved in pre- and post-MTX in vitro fertilization cycles was similar (UpToDate, ectopic pregnancy, 2026).
Last updated: .